Citations

Clear

595 citation(s) found for "Parikh, K".

Abstract 3931: Immune cell profile changes in patients treated with tarlatamab for extensive stage small cell lung cancer in real world practice.
Prasad, Dhauna Karam, Corraes, Andre De Menezes Silva, Gupta, Malvika , Ma, Audrey, Wu, Chen , Shao, Zuoyi, Reagan, K J, Kamal, Rayaan, Potter, Ashley , Al-Ajmi, Abdullah, Mina, Syeda A. , Taylor, Sykler J., Dimou, A., Parikh, K., Luce, A., Schwecke, Anna, Molina, Julian R , Mansfield, Aaron S., Holmes, Lucy , Dong, Haidong, Lin, Yi, Leventakos, Konstantinos , Corraes, Andre De Menezes Silva , Ma, Audrey, Shao, Zuoyi, Kamal, Rayaan, Al‐Ajmi, Abdullah, Hazim, Antonious , Shanshal, Mohammed , Molina, Julian R. , Mansfield, Aaron S., Smith, Katherine E. , Holmes, Lucy

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 3931-3931

10.1158/1538-7445.am2026-3931 Get It

Abstract Background: Tarlatamab, a Delta-like ligand (DLL3)/CD3-targeted bispecific T-cell engager (TCE) is FDA approved in patients (pts) with extensive stage small cell lung cancer (ES-SCLC), after progression on frontline chemoimmunotherapy. We aimed to evaluate the immune cell profile in pts who received this therapy in standard-of-care (SOC) practice with progression free survival (PFS) less than and greater than two months (mo). Methods: Patients who received tarlatamab at Mayo Clinic Rochester and consented to immuno phenotyping of blood are included in the present study. Immune phenotyping was performed on whole blood by flow cytometry and analyzed by Kaluza. Data analysis was performed with Microsoft Excel and PRISM. Results: Eighteen patients with median age 64 (range 37-79) were included in the study. 66% of our cohort were women and 83% had present or past history of smoking, with an average of 40 pack years (range 26-60). With a median follow-up of 2 months, the median PFS for the cohort was 1.5 mo (range 0.33-2.76 months). 61% (13/18) of patients had PFS <2mo. 39% (5/18) had PFS>2mo and of which, three patients had partial response with one maintaining stable disease and one patient with mixed response. At baseline (BL), there were no difference in T cell, CD4 or CD8 cell count between patients in the PFS<2mo and PFS>2mo groups. Patients with PFS<2mo had higher exhausted CD8 T cells compared to those in the PFS>2mo group (CD8+PD1+TIGIT+CD57+, PFS<3mo vs >3mo, cells/mL: 7.14±4.28, 1.58±1.37, p=0.009). Additionally, when analyzing the B-cell population, the PFS<2mo group had lower percentage of B cells compared to the group with PFS>2mo at baseline (6.0±7.5, 10.4±14, p=0.02). At day 7, the group with PFS<2mo had lower Treg compared to the group with PFS>2mo (2.88±1.38, 4.60±1.47, p=0.02). Also, the PFS<2mo group had an increase of B cells compared to the group with PFS>2mo at day 7(<2mo vs >2mo: 10.0±14, 4.37±3.07, p=0.04). Finally, the group with PFS>2mo had decrease in total monocytes (mono), classical mono, and immunosuppressive cells (PFS<2mo vs >2mo, Mono: 340±347, 253±106, p=0.04. Classical mono: 305±283, 155±109, p=0.02. CD14+HLA-DRneg: 105.8±96, 12±39, p=0.03) compared to the group with PFS<2mo by day 7. While no changes were seen between BL and day 7 for intermediate mono in PFS<2mo group, PFS>2mo group had decreased post treatment intermediate monocytes (BL vs day 7, cells/mL, intermed mono: 32.5±15,17.7±6.2, p=0.03). Conclusion: In this study investigating the SOC outcomes of tarlatamab, early progression was associated with higher presence of exhausted CD8 T cells, B cells, and immunosuppressive monocytes. Analysis of additional patients will be shared at AACR meeting. Citation Format: Dhauna Karam Prasad, Andre De Menezes Silva Corraes, Malvika Gupta, Audrey Ma, Chen Wu, Zuoyi Shao, Kevin Reagan, Rayaan Kamal, Ashley Potter, Abdullah Al-Ajmi, Syeda Mina, Sykler J. Taylor, Antonious Hazim, Anastasios Dimou, Kaushal Parikh, Mohammed Shanshal, Ailsa Luce, Anna Schwecke, Julian Molina, Aaron Mansfield, Katherine Smith, Lucy Holmes, Haidong Dong, Yi Lin, Konstantinos Leventakos. Immune cell profile changes in patients treated with tarlatamab for extensive stage small cell lung cancer in real world practice [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3931.
Abstract 1183: Early ctDNA quantification by ctFE outperforms Max VAF for survival stratification across locally advanced and oligometastatic NSCLC treated with radiotherapy.
Hashmi, Ayesha , Linford, Jessica , Parikh, K., Ben-Shachar, Rotem, Guittar, John , Pillai, Malvika , Patel, Jyoti D., Bergsagel, Matteo , Olivier, K., Park, Sean S., Owen, Dawn, Lee, K.N. , Sherry, Alex, Morgensztern, Daniel , Ferreira, Bruna Pellini, Vlacich, Gregory , Chaudhuri., Aadel A., Chauhan, Pradeep S. , Ben‐Shachar, Rotem , Semenkovich, Nicholas P. , Routman, David M. , Mansfield, Aaron S. , Govindan, Ramaswamy , Robinson, Clifford G. , Bergom, Carmen , Waqar, Saiama N , Chaudhuri, Aadel A.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 1183-1183

10.1158/1538-7445.am2026-1183 Get It

Abstract Background: Personalizing chemoradiotherapy (chemoRT) for locally advanced non-small cell lung cancer (LA-NSCLC) is limited by the lack of early biomarkers that inform response during treatment. Current circulating tumor DNA (ctDNA) molecular residual disease assays predict post-treatment outcomes but lack mid-treatment utility. ctDNA burden estimation has traditionally relied on variant-centric metrics such as maximum variant allele fraction (Max VAF), which rely on mutation-specific signals and may be confounded by histology-dependent shedding variability, allelic imbalance, and clonal hematopoiesis. Here we present circulating tumor fraction estimate (ctFE), a machine-learning composite score that integrates VAF distributions, copy-number alterations, and germline B-allele frequency deviations to approximate global tumor burden using a widely available, tumor-naïve clinical platform. Methods: A burden-based ctFE threshold was derived using pre-treatment plasma from a prospective phase II clinical trial of MR-guided hypofractionated chemoRT (LA-WU, n=26), locked, and applied unchanged to early mid-treatment samples (day 10-14). To test scalability and generalizability, its prognostic performance was validated in two real-world cohorts: 94 LA-NSCLC patients receiving definitive chemoRT (LA-RW) and 309 oligometastatic NSCLC patients receiving consolidative RT (OM-RW). ctFE and Max VAF were compared as continuous predictors across cohorts. Results: ctFE consistently outperformed Max VAF. In LA-WU, pre-treatment ctFE was associated with overall survival (OS HR=1.15, p=0.04) and progression-free survival (PFS HR=1.84, p=0.009), whereas Max VAF was not. Mid-treatment ctFE remained prognostic for PFS (HR=1.14, p=0.026). Early ctFE dynamics defined three molecular response groups with marked OS separation: consistently low, responder, and nonresponder groups (median OS 60.8 vs 13.0 vs 2.9 months, respectively; p<0.001). In multivariable models including both biomarkers, higher ctFE remained independently associated with worse survival in LA-RW (OS HR=1.88, p=0.010) and OM-RW (OS HR=1.37, p=0.040; PFS HR=1.45, p=0.008), whereas Max VAF did not. The locked ctFE threshold stratified OS across all cohorts (LA-WU HR=5.93; LA-RW HR=9.08; OM-RW HR=2.26; all p<0.001). Conclusion: ctFE provides clinically meaningful pre- and mid-treatment risk stratification and consistently outperforms Max VAF across locally advanced and oligometastatic NSCLC cohorts. We show that ctFE is a biologically informative, clinically generalizable and scalable ctDNA burden metric measurable using a tumor-naïve, off-the-shelf assay, supporting its practical utility in biomarker-adapted radiotherapy strategies. Citation Format: Ayesha Hashmi, Jessica Linford, Pradeep S. Chauhan, Kaushal Parikh, Rotem Ben-Shachar, John Guittar, Malvika Pillai, Jyoti Patel, Matteo Bergsagel, Nicholas P. Semenkovich, Kenneth R. Olivier, Sean S. Park, Dawn Owen, David M. Routman, Katie N. Lee, Alex D. Sherry, Aaron S. Mansfield, Daniel Morgensztern, Ramaswamy Govindan, Clifford G. Robinson, Carmen Bergom, Saiama N. Waqar, Bruna Pellini Ferreira, Gregory R. Vlacich, Aadel A. Chaudhuri. Early ctDNA quantification by ctFE outperforms Max VAF for survival stratification across locally advanced and oligometastatic NSCLC treated with radiotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1183.
A guide to neuromodulation in drug‐resistant epilepsy
Parikh, Prachi, Dolezawa, Irena, Hegde, Manu , Imbach, L., Rao, Vikram R., Singh, Jaysingh , Watanabe, Satsuke, Frauscher, B., Frauscher, Birgit , Parikh, Prachi, Imbach, Lukas , Lundstrom, Brian N. , Pizzo, Francesca , Rao, Vikram R. , Southwell, Derek G. , Frauscher, Birgit

Mayo Clinic

Epileptic Disorders | March 27, 2026 | Volume: 28 | Issue: 4 | Pages: 953-980

10.1002/epd2.70221 | PMID 41894177 Get It

Abstract Neuromodulation is approved for the treatment of drug‐resistant epilepsy. It has been increasingly utilized over the past two decades with the approval of deep brain stimulation (DBS) and responsive neurostimulation (RNS) in addition to vagus nerve stimulation (VNS)—particularly in patients who are not deemed to be good resective surgical candidates or in case of patient preference. In this seminar in epileptology article, we address learning objective 3.7 “Demonstrate knowledge of indications, limitations and risks for vagal nerve stimulation and other neuromodulation techniques” of the International League Against Epilepsy curriculum for epileptologists. We will review the indications for neuromodulation, device programming, surgical considerations for implantation, side effects, effects on sleep, and mood. This is complemented by case examples that provide perspective for trainees, along with an outlook on future directions for neuromodulation in epilepsy. This article aims to serve as a learning resource for trainees in neurology, clinical neurophysiology, and epileptology by providing guidance in how to navigate the landscape of neuromodulation in epilepsy.
High Soluble Tumor Necrosis Factor Receptor 2 in Serum Is Associated With Inferior Overall Survival Across Major Lymphoma Subtypes
Khurana, Arushi , Hayashi, Hikaru, Thach, Bethany J., Yang, Zhi Zhang, Negaard, Brianna J., Cerhan, James R., Novak, Anne J. , Habermann, Thomas M., Feldman, Andrew L., Parikh, S., Slager, Susan L., Ansell, Stephen M., Maurer, Matthew J., Faustman, D L, Habermann, Thomas M. , Cerhan, James R. , Cerhan, James R , Habermann, Thomas , Slager, Susan L , Ansell, Stephen M , Maurer, Matthew , Novak, Anne J , Hayashi, Hikaru, Gysbers, Brianna J. , Link, Brian K. , Feldman, Andrew L. , Parikh, Sameer A. , Slager, Susan L. , Ansell, Stephen M. , Maurer, Matthew J.

Mayo Clinic

American Journal of Hematology | March 27, 2026 | Volume: 101 | Issue: 6 | Pages: 1388-1397

10.1002/ajh.70293 | PMID 41891328 Get It

ABSTRACT Soluble tumor necrosis factor receptor 2 (sTNFR2) is a member of the TNF superfamily whose normal bodily distribution is largely limited to low level expression on lymphoid cells. It has emerged as an important inducible receptor that activates a signaling pathway for cancer growth. We evaluated sTNFR2 as a prognostic biomarker for overall survival (OS) in newly diagnosed lymphoma using a prospective cohort study with banked pretreatment serum samples. sTNFR2 was higher in 1513 lymphoma patients compared to 499 age and sex matched controls ( p < 0.0001). Using Kaplan–Meier curves and Cox proportional hazards models to estimate hazard ratios [HR] (high vs. low tertile), higher levels of sTNFR2 at diagnosis were associated with inferior OS across all seven major lymphoma subtypes: Hodgkin lymphoma ( p < 0.0001; HR = 12.6), diffuse large B‐cell lymphoma ( p < 0.0001; HR = 2.6), follicular lymphoma ( p = 0.00017; HR = 2.5), mantle cell lymphoma ( p < 0.0001; HR = 4.2), small lymphocytic lymphoma ( p = 0.012; HR = 2.4), marginal zone lymphoma ( p = 0.0012; HR = 3.1), and T‐cell lymphoma ( p < 0.0001; HR = 3.1). Using CITE‐seq profiling of tumor microenvironment tissue, we sought to identify cellular source(s) of circulating sTNFR2. In tumor tissue from follicular lymphoma, high TNFR2‐expressing cells were found to be T‐regulatory (Treg) cells, suggestive of a Treg‐driven cancer. In tissue from a case of marginal zone lymphoma, high TNFR2 expression was found on CD4+ and CD8+ T cells, B cells, and monocytes but also directly on tumor cells. We conclude sTNRF2 is a strong prognostic biomarker of OS across major lymphoma subtypes and may be useful to guide therapeutic choices, including targeted therapies against immunosuppressive TNFR2‐expressing Tregs.
Training for pediatric cannot intubate cannot oxygenate: surgical airway should replace needle cricothyrotomy
Lehman, Allison M.B., Amstutz, Paul, Moore, Jackson E. , Obersteadt, Christopher, Williams, Dominique, Waxman, Mary J., Blubaugh, Morgan , Parikh, Anaya, Walsh, Timothy R., Bruegger, Daniel E., Malik, Adrienne , Pirotte, Andrew, Johnson, Matthew D. , Obersteadt, Chris, Sood, Shawn , Pirotte, Andrew P.

Mayo Clinic

Frontiers in Disaster and Emergency Medicine | March 17, 2026 | Volume: 4 | Issue: No issue available | Pages: No page available

10.3389/femer.2026.1772381 | PMID 41928873 Get It

Failed pediatric endotracheal intubation, prompting surgical airway management via emergency front of neck access (eFONA), is an intrinsically challenging topic. While rare, all emergency airway providers must be equipped to handle these complex clinical scenarios, both through initial training and maintenance of competency. Needle cricothyrotomy is a commonly taught method in cannot intubate cannot oxygenate (CICO) scenarios for children under age eight. However, needle cricothyrotomy is technically difficult, profoundly rare, and maintaining competency is a challenge. From a multidisciplinary perspective, we examine the utility of continuing to teach needle cricothyrotomy and explore alternatives. This project group suggests that pediatric eFONA training across disciplines should focus on surgical tracheotomy rather than needle cricothyrotomy, with consideration given to specialty-specific human performance factors.
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026
Wierda, William G., Brown, Jennifer, Abramson, Jeremy, Bociek, Greg, Boyer, Daniel F. , Cortese, Matthew J , Cripe, Larry D., D’Angelo, Christopher R. , Darnell, Elijah P., Davis, Randall S. , Eradat, Herbert, Esteghamat, Naseem , Fitzgerald, Lindsey , Fletcher, Christopher D., Gaballa, Sameh , Kamdar, Manali, Kipps, Thomas J., Ma, Shuo, Nakhoda, Shazia, Schorr, Andrew, Schuster, Stephen, Seshadri, Madhav, Shanafelt, T., Ujjani, Chaitra, Wagner-Johnston, Nina, Woyach, Jennifer A. , Dwyer, Mary, Sundar, Hema, Shanafelt, Tait D. , Shanafelt, Tait D , Wierda, William G. , Abramson, Jeremy S. , Awan, Farrukh T. , Huntington, Scott F. , Kahl, Brad S. , Kamdar, Manali , Kipps, Thomas J. , Ma, Shuo, Mosse, Claudio A. , Nakhoda, Shazia , Parikh, Sameer A. , Riedell, Peter A. , Seshadri, Madhav , Siddiqi, Tanya , Sitlinger, Andrea Phillips , Thompson, Meghan C , Ujjani, Chaitra S. , Wagner‐Johnston, Nina D. , Dwyer, Mary A.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 12, 2026 | Volume: 24 | Issue: 3 | Pages: 68-80

10.6004/jnccn.2026.0012 | PMID 41825137 Get It

Bruton tyrosine kinase inhibitors (BTKis) and BCL2 inhibitor (BCL2i)–containing regimens significantly improve survival outcomes in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Results from randomized clinical trials have demonstrated that time-limited treatment with BCL2i-containing regimens resulted in higher rates of undetectable measurable residual disease (uMRD) than BTKi monotherapy or chemoimmunotherapy (CIT). Pirtobrutinib (a noncovalent BTKi) and lisocabtagene maraleucel (CD19-directed CAR T-cell therapy) are newer options for relapsed or refractory disease after prior therapy with BTKi and BCL2i-contining regimens. Histologic transformation of CLL/SLL to diffuse large B-cell lymphoma (Richter transformation) is associated with a poor prognosis. Molecular analysis to determine whether there is clonal relationship between CLL/SLL and transformed diffuse large B-cell lymphoma is useful to select an appropriate treatment option. These NCCN Guideline Insights highlight significant updates to the NCCN Guidelines for the treatment of CLL/SLL and Richter transformation.
The PRECIsE Study: a prospective, multicenter study of shape-sensing robotic-assisted bronchoscopy with two years of follow-up
Ost, David E, Reisenauer, Janani S, Majid, A., Casal, Roberto F, Keyes, Colleen , Parikh, Mihir , Diaz‐Mendoza, Javier , Fernandez-Bussy, Sebastian, Simoff, Michael J, Ost, David E. , Folch, Erik E. , Reisenauer, Janani , Majid, Adnan , Casal, Roberto F. , Fernández-Bussy, Sebastián , Simoff, Michael

Mayo Clinic

Annals of the American Thoracic Society | March 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/annalsats/aaoag049 | PMID 41773028 Get It

Abstract INTRODUCTION Guidelines recommend non-surgical biopsy for indeterminate pulmonary lesions &gt; 8 mm. Shape-sensing robotic-assisted bronchoscopy (ssRAB) is growing in use to biopsy small pulmonary nodules; however current literature is limited to single center studies with limited follow-up. This study, PRECIsE, assessed safety and performance of the first ssRAB iteration across multiple sites and nascent users. METHODS Prospective, multicenter, observational study evaluating ssRAB without cone-beam CT guidance in patients with nodules 10–30 mm located in or beyond the sub-segmental airways. Patients were followed for 2 years; the primary endpoint was sensitivity for malignancy with diagnostic yield, and safety as secondary endpoints. Multilevel logistic regression models were used to control for factors associated with sensitivity and diagnostic yield. RESULTS A total of 305 procedures were performed across 6 centers. Median nodule size was 17.0 mm (IQR: 14.0–23.0) with bronchus sign present in 37% of cases. Sensitivity for malignancy through 2 years was 81.3% (95% CI: 75.7, 86.1). Multi-level modelling demonstrated female sex, smaller nodule size, lower lobe location, semi-solid density, and higher body-mass-index were associated with lower sensitivity. Diagnostic yield was 74.1% (95% CI: 68.8, 78.9) according to the ATS/ACCP criteria and 77.5% [95% CI: 72.4, 81.8] according to the intermediate criteria. Multi-level modeling demonstrated a non-significant site/center level effect on ATS/ACCP diagnostic yield (P = .36). Pneumothorax requiring intervention was 1.6% (5/305); bleeding was 1.0% (3/305) with two (2) Nashville grade 2 and one (1) Nashville grade 3 events. CONCLUSIONS The first iteration of ssRAB demonstrated encouraging performance and a strong safety profile among nascent users for the biopsy of small peripheral nodules.
Validation of longitudinal biomarker screening algorithms for HCC detection in patients with cirrhosis
Singal, Amit G., Marrero, Jorge, Parikh, Neehar D. , Lok, Anna S., Lopez, Camden, Page-Lester, Stephanie, Roberts, Lewis R., Reddy, Rajender, Luster, Michelle, Khaderi, Saira, El-Serag, Hashem B., Kanwal, Fasiha, Ziding, Feng, Tayob, Nabihah, Roberts, Lewis R. , Roberts, Lewis R , Parikh, Neehar D , Singal, Amit G. , Jin, Qingchun , Lok, Anna S. , Asrani, Sumeet K. , El‐Serag, Hashem B. , Kanwal, Fasiha

Mayo Clinic

Hepatology Communications | February 23, 2026 | Volume: 10 | Issue: 3 | Pages: No page available

10.1097/hc9.0000000000000902 | PMID 41730232 Get It

Background: Blood-based biomarker panels, including GALAD, have been proposed as an alternative to abdominal ultrasound for hepatocellular carcinoma (HCC) surveillance. Studies suggest longitudinal evaluation of biomarkers can improve test performance; however, no large studies have validated these findings. Methods: We leveraged the HCC Early Detection Strategy (HEDS) study (n=1019 patients with cirrhosis; 99 incident HCC) and Texas HCC Consortium (THCCC) (n=2345 patients with cirrhosis; 126 incident HCC) to compare the performance of fixed-threshold GALAD (cutoff of −1.36), and 4 longitudinal algorithms: longitudinal GALAD, PALAD, mFB-ALAD, and mPEB-ALAD. The HEDS cohort was used to derive longitudinal algorithms, and external validation was performed in THCCC. Patient-level sensitivity and test-level false-positive rate (FPR) were examined overall and across subgroups by age, sex, and cirrhosis etiology. Results: In THCCC, fixed-threshold GALAD had higher sensitivity in the 6 months before HCC diagnosis (71.4%, 95% CI: 62.9%–81.7%) than longitudinal GALAD (55.1%, 95% CI: 49.3–66.4), PALAD (55.1%, 95% CI: 50.0%–70.5%), mPEB-ALAD (53.1%, 95% CI: 43.6%–62.0%), and mFB-ALAD (42.9%, 95% CI: 32.3–48.5). However, fixed-threshold GALAD had a higher FPR (25.4%, 95% CI: 23.7%–26.9%) compared with longitudinal GALAD (15.0%, 95% CI: 12.8%–15.8%), PALAD (13.0%, 95% CI: 10.2%–14.6%), and mFB-ALAD (11.2%, 95% CI: 9.6%–12.1%) but comparable to mPEB-ALAD (22.9%, 95% CI: 21.2%–23.8%). In subgroup analyses, fixed-threshold GALAD had the highest FPR in males (35.6%) and those aged ≥65 (43.5%); longitudinal algorithms had significantly lower FPRs in subgroups but with lower sensitivity for HCC. Conclusions: Improvements in FPRs with longitudinal GALAD algorithms, as compared with fixed-threshold GALAD, are offset by significantly decreased sensitivity for HCC detection.
Diagnosis and Treatment of Nontraumatic Osteonecrosis of the Femoral Head: A Systematic Review and Meta-Analyses for the ARCO Clinical Practice Guideline Development Workgroup
Parikh, Romil, Mirzaei, Alireza, Butler, Mary E., Restrepo, Diego J. , Perez, Sergio F. Guarin , Brandt, Sallee , Swartz, Gabrielle, Katanbaf, Reza , Goodman, Stuart B. , Mont, M. Isabel Matilla, CUI, QUANJUN , Jones, Lynne C. , Cheng, Edward Y., Goodman, Stuart B. , Restrepo, Diego J. , Parikh, Romil R , Guarin Perez, Sergio F , Mirzaei, Alireza , Swartz, Gabrielle N , Mont, Michael A.

Mayo Clinic

Medical Sciences | February 23, 2026 | Volume: 14 | Issue: 1 | Pages: 107

10.3390/medsci14010107 | PMID 41892822 Get It

Background/Objectives: Diagnostic evaluation and management of nontraumatic osteonecrosis of the femoral head (ONFH) vary substantially. This systematic review was conducted to inform development of the Association Research Circulation Osseous (ARCO) clinical practice guideline for diagnosis and treatment of ARCO stages I to III ONFH. Methods: We searched MEDLINE, EMBASE, Web of Science, SCOPUS, Global Index Medicus, and the Cochrane Library for studies evaluating imaging modalities and treatments for adult ONFH. We assessed risk of bias using the QUADAS-2, the ROB-2, and the ROBINS-I tools; conducted meta-analyses using random-effects regression; and evaluated certainty of evidence using GRADE methodology. Results: Among 36 included studies, 18 addressed diagnostic test accuracy and 18 addressed comparative effectiveness of treatments. Magnetic resonance imaging (MRI) demonstrated the highest pooled sensitivity (0.91; 95% confidence interval (CI), 0.87 to 0.94) and specificity (0.96; 95% CI, 0.87 to 0.99) for ONFH diagnosis. Bone marrow edema and grade 2+ joint effusion on MRI differentiated symptomatic versus asymptomatic disease. Computed tomography and MRI better detected subchondral fractures than plain radiography. Very low-grade evidence suggested lower rates of femoral head collapse with core decompression plus bone marrow concentrate compared with core decompression alone (pooled relative risk [RR], 0.55; 95% CI, 0.36 to 0.83), and with vascularized versus non-vascularized bone grafting (RR, 0.35; 95% CI, 0.14 to 0.84) over a ≤5-year follow-up. Based on three non-comparative case series, osteotomies might have a lower risk of collapse over a 10- to 20-year follow-up, but this needs to be evaluated in future comparative research. Inconsistent outcome reporting hindered treatment outcome pooling. There were no comparative studies that evaluated observation only versus intervention in asymptomatic disease or strategies for monitoring treatment response. Conclusions: Evidence supporting optimal imaging modalities and early joint-preserving interventions remains limited and predominantly observational, underscoring the need for high-quality comparative studies with consistently defined core outcomes to guide clinical decision-making.